ADURO BIOTECH, INC. (a Delaware corporation) [—] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 6th, 2015 • Aduro Biotech, Inc. • Pharmaceutical preparations • New York
Aduro Biotech, Inc., a Delaware corporation (the “Company”), confirms its agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”), Leerink Partners LLC (“Leerink”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch and Leerink are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of [—] additional shares of Common Stock. The aforesaid [—] shares of Com
ADURO BIOTECH, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • April 6th, 2015 • Aduro Biotech, Inc. • Pharmaceutical preparations • Delaware
THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of March 12, 2015 (the “Execution Date”) by and between Aduro Biotech, Inc., a Delaware corporation (the “Company”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation (the “Investor”).
ADURO BIOTECH, INC. SERIES E PREFERRED STOCK PURCHASE AGREEMENTSeries E Preferred Stock Purchase Agreement • April 6th, 2015 • Aduro Biotech, Inc. • Pharmaceutical preparations • Delaware
THIS SERIES E PREFERRED STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of March 12, 2015 (the “Execution Date”) by and between Aduro Biotech, Inc., a Delaware corporation (the “Company”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation (the “Investor”).
COLLABORATION AND LICENSE AGREEMENT dated as of March 12, 2015 between ADURO BIOTECH, INC. and NOVARTIS PHARMACEUTICALS CORPORATIONCollaboration and License Agreement • April 6th, 2015 • Aduro Biotech, Inc. • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of March 12, 2015 (the “Execution Date”) by and between Aduro Biotech, Inc., a Delaware corporation having its principal place of business at 626 Bancroft Way, #3C, Berkeley, CA 94710-2224 (“Company”), and Novartis Pharmaceuticals Corporation, a Delaware Corporation having its principal place of business in located at One Health Plaza, East Hanover, New Jersey 07936, (“Novartis”). Novartis and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
